Spreadsheet: 8d6aae77-4eec-4857-af5e-7f5538b0ac4a
Sheet: Sheet1

Broad connectivity analysis of Age signature
 | [NAME] | pharmacology | mean | n | enrichment | p | specificity | percent non-null
57 | antazoline | antihistamine/ anticholinergic | 0.598 | 4 | 0.633 | 0.04474 | 0.0392 | 75 |  | negative = opposite of ageing
46 | puromycin | inhibits elongation during protein synth | 0.551 | 4 | 0.659 | 0.03113 | 0.3315 | 75 |  | positive = same direction as ageing
17 | dicycloverine | anticholinergic | 0.55 | 5 | 0.715 | 0.00439 | 0.0055 | 80
61 | tribenoside |  | 0.502 | 4 | 0.629 | 0.04752 | 0.1005 | 75
42 | thapsigargin | SERCA inhibitor | 0.475 | 3 | 0.766 | 0.02542 | 0.2102 | 66
25 | chlorhexidine | membrane disruption | 0.471 | 5 | 0.674 | 0.00951 | 0 | 80
18 | thioperamide | histamine H3 antagonist | 0.464 | 5 | 0.712 | 0.00467 | 0.0225 | 80
28 | Prestwick-691 | ? | 0.464 | 3 | 0.817 | 0.01212 | 0.0375 | 66
14 | benzamil | sodium channel blocker | 0.461 | 6 | 0.683 | 0.0026 | 0.0255 | 83
45 | loperamide | opioid-receptor agonist | 0.455 | 6 | 0.552 | 0.03045 | 0.1717 | 66
27 | yohimbic acid | ? | 0.445 | 3 | 0.821 | 0.01154 | 0.007 | 66
59 | cicloheximide | inhibits elongation during protein synth | 0.433 | 4 | 0.632 | 0.04559 | 0.3107 | 75
15 | metitepine | serotonin and dopamine antag | 0.43 | 4 | 0.782 | 0.00422 | 0.0152 | 75
34 | 3-hydroxy-DL-kynurenine |  | 0.423 | 6 | 0.584 | 0.01764 | 0 | 66
65 | pralidoxime |  | 0.413 | 4 | 0.62 | 0.05278 | 0.078 | 75
60 | alverine |  | 0.411 | 4 | 0.629 | 0.04697 | 0.0062 | 75
19 | [PHONE] |  | 0.41 | 4 | 0.774 | 0.00495 | 0 | 75
56 | doxylamine |  | 0.404 | 5 | 0.581 | 0.03991 | 0.072 | 60
43 | PHA-00767505E |  | 0.375 | 4 | 0.671 | 0.02572 | 0.0129 | 75
24 | [NAME] |  | 0.353 | 4 | 0.739 | 0.00903 | 0.0055 | 75
32 | vigabatrin |  | 0.342 | 3 | 0.809 | 0.0142 | 0.0412 | 66
44 | lycorine |  | 0.339 | 5 | 0.608 | 0.02784 | 0.2716 | 60
5 | LY-294002 | PI3K and CK2 inhib | 0.338 | 61 | 0.391 | 0 | 0.1544 | 54
23 | iohexol |  | 0.328 | 4 | 0.742 | 0.00847 | 0.0171 | 50
38 | clindamycin |  | 0.326 | 5 | 0.626 | 0.02127 | 0.0217 | 60
48 | foliosidine |  | 0.304 | 6 | 0.548 | 0.0323 | 0.0469 | 66
12 | etiocholanolone |  | 0.292 | 6 | 0.692 | 0.0022 | 0.0317 | 50
51 | eticlopride |  | 0.264 | 4 | 0.653 | 0.0339 | 0.1056 | 50
37 | podophyllotoxin |  | 0.246 | 4 | 0.694 | 0.0182 | 0.1905 | 50
31 | levothyroxine sodium |  | 0.239 | 4 | 0.718 | 0.01307 | 0.0204 | 50
54 | myosmine |  | 0.148 | 6 | 0.541 | 0.03574 | 0.0992 | 50
20 | flunisolide |  | -0.185 | 6 | -0.643 | 0.0058 | 0 | 66
63 | niridazole |  | -0.206 | 4 | -0.624 | 0.04937 | 0.0601 | 50
62 | metacycline |  | -0.231 | 4 | -0.625 | 0.04852 | 0.1658 | 75
53 | ganciclovir |  | -0.264 | 4 | -0.65 | 0.03527 | 0.0226 | 75
26 | guaifenesin |  | -0.268 | 6 | -0.612 | 0.01102 | 0.0309 | 66
35 | thiocolchicoside |  | -0.268 | 4 | -0.696 | 0.0181 | 0.0183 | 50
49 | harmine |  | -0.268 | 4 | -0.656 | 0.03235 | 0.1492 | 50
22 | [PHONE] |  | -0.274 | 8 | -0.551 | 0.00814 | 0.0203 | 62
33 | 3-acetylcoumarin |  | -0.285 | 5 | -0.643 | 0.01446 | 0.016 | 60
29 | oxprenolol |  | -0.287 | 4 | -0.721 | 0.01239 | 0.0149 | 50
36 | glipizide |  | -0.291 | 5 | -0.629 | 0.0181 | 0.0237 | 60
52 | picotamide |  | -0.301 | 5 | -0.589 | 0.03446 | 0.0556 | 60
30 | cycloserine |  | -0.302 | 4 | -0.719 | 0.01259 | 0.033 | 50
11 | progesterone |  | -0.303 | 4 | -0.815 | 0.00215 | 0 | 75
39 | [NAME] |  | -0.313 | 4 | -0.684 | 0.02178 | 0.1026 | 50
66 | trimethadione |  | -0.328 | 4 | -0.616 | 0.05498 | 0.0536 | 75
64 | withaferin A | Withaferin A is a potent inhibitor of angiogenesis. Withaferin A inhibits both NF-kB and Sp1 Transcription factor activity | -0.339 | 4 | -0.621 | 0.0519 | 0.1803 | 75
13 | ellipticine | inhibition of topoisomerase | -0.34 | 4 | -0.812 | 0.00243 | 0.0305 | 50
58 | mercaptopurine | inhibits purine nucleotide synthesis | -0.384 | 2 | -0.85 | 0.04503 | 0.0274 | 100
55 | amrinone | PDEIII inhbitor - used in CHF | -0.408 | 4 | -0.647 | 0.03702 | 0.0909 | 75
16 | pirlindole | MOA inhibitor | -0.417 | 3 | -0.871 | 0.00423 | 0.0068 | 100
41 | irinotecan | inhibition of topoisomerase | -0.417 | 3 | -0.774 | 0.02362 | 0.163 | 66
47 | verteporfin | erteporfin in the treatment of predominantly classic neovascular age-related macular degeneration; yields ROS when photoactivated | -0.434 | 3 | -0.749 | 0.03229 | 0.093 | 66
40 | sulfanilamide | antibiotic | -0.441 | 4 | -0.683 | 0.02216 | 0.0056 | 75
8 | securinine | [NAME] ? | -0.443 | 4 | -0.854 | 0.00084 | 0.0127 | 100
50 | esculin | glucoside | -0.446 | 4 | -0.654 | 0.03312 | 0.0157 | 75
9 | 3-nitropropionic acid | Complex II inhibitor? | -0.45 | 4 | -0.849 | 0.00095 | 0 | 100
21 | mitoxantrone | type II topoisomerase inhibitor | -0.507 | 3 | -0.845 | 0.00747 | 0.0567 | 66
10 | azacitidine | nucleoside | -0.555 | 3 | -0.903 | 0.00172 | 0.0673 | 100
7 | [PHONE] | ? | -0.589 | 6 | -0.793 | 0.00016 | 0.0352 | 83
6 | camptothecin | DNA topoisomerase | -0.707 | 3 | -0.972 | 8e-05 | 0.0796 | 100
3 | doxorubicin | DNA cheltation | -0.755 | 3 | -0.99 | 0 | 0.015 | 100
4 | H-7 | [NAME]?? | -0.799 | 4 | -0.989 | 0 | 0.0303 | 100
1 | GW-8510 | CDK2 inhibitor, P53 activation | -0.825 | 4 | -0.996 | 0 | 0 | 100
2 | alsterpaullone | CDK inhibitor | -0.885 | 3 | -0.992 | 0 | 0.0214 | 100